
A study, "Iron and Phosphaturia – ExplorIRON-CKD," investigated the impacts of Ferric Derisomaltose (FDI) and Ferric Carboxymaltose (FCM) on bone health markers in non-dialysis-dependent CKD patients. The trial involved 26 participants randomly assigned to FDI or FCM. Results showed FCM significantly increased intact FGF23 levels compared to FDI, potentially affecting vitamin D metabolism and bone turnover. Phosphate levels decreased notably with FCM. FCM induced more substantial changes in bone turnover markers compared to FDI. These findings suggest disparate effects of intravenous iron formulations on bone health in CKD patients, necessitating further research for clinical insights.
Like
Save
Share